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a b s t r a c t
Hypertension induces left-ventricular hypertrophy (LVH) by mechanisms involving oxidative stress and
unbalanced cardiac matrix metalloproteinase (MMP) activity. We hypothesized that β1-adrenergic
receptor blockers with antioxidant properties (nebivolol) could reverse hypertension-induced LVH more
effectively than conventional β1-blockers (metoprolol) when used at doses that exert similar anti-
hypertensive effects. Two-kidney one-clip (2K1C) hypertension was induced in male Wistar rats. Six
weeks after surgery, hypertensive and sham rats were treated with nebivolol (10 mg kg1 day1) or
metoprolol (20 mg kg1 day1) for 4 weeks. Systolic blood pressure was monitored weekly by tail-cuff
plethysmography. LV structural changes and ﬁbrosis were studied in hematoxylin/eosin- and picrosirius-
stained sections, respectively. Cardiac MMP levels and activity were determined by in situ zymography,
gel zymography, and immunoﬂuorescence. Dihydroethidium and lucigenin-derived chemiluminescence
assays were used to assess cardiac reactive oxygen species (ROS) production. Nitrotyrosine levels were
determined in LV samples by immunohistochemistry and green ﬂuorescence and were evaluated using
the ImageJ software. Cardiac protein kinase B/Akt (AKT) phosphorylation state was assessed by Western
blot. Both β-blockers exerted similar antihypertensive effects and attenuated hypertension-induced
cardiac remodeling. Both drugs reduced myocyte hypertrophy and collagen deposition in 2K1C rats.
These effects were associated with lower cardiac ROS and nitrotyrosine levels and attenuation of
hypertension-induced increases in cardiac MMP-2 levels and in situ gelatinolytic activity after treatment
with both β-blockers. Whereas hypertension increased AKT phosphorylation, no effects were found with
β-blockers. In conclusion, we found evidence that two β1-blockers with different properties attenuate
hypertension-induced LV hypertrophy and cardiac collagen deposition in association with signiﬁcant
cardiac antioxidant effects and MMP-2 downregulation, thus suggesting a critical role for β1-adrenergic
receptors in mediating those effects. Nebivolol is not superior to metoprolol, at least with respect to their
capacity to reverse hypertension-induced LVH.
& 2014 Elsevier Inc. All rights reserved.
Hypertension is a major risk factor for cardiovascular events [1]
at least in part attributable to cardiac remodeling associated with
left-ventricular hypertrophy (LVH), which may lead to heart failure
[2]. Despite the alterations triggered by chronic hypertension on
cardiomyocytes, important modiﬁcations also occur in the cardiac
extracellular matrix (ECM) integrity during the progression of LVH
[3–5]. Intense collagen deposition promotes myocardial stiffening
and impairs myocardial function in association with the cardiac
hypertrophy of hypertension [6,7].
Matrix metalloproteinases (MMPs) are critically involved in the
turnover of cardiac ECM, and unbalanced MMP activity usually
results in ﬁbrosis [8–10]. Innumerous studies have shown that,
among other members, MMP-2 activity plays a key role in
hypertensive cardiac remodeling and in other cardiovascular
disorders [9,11–14]. This enzyme is activated under conditions
that increase the formation of reactive oxygen species (ROS)
[10,15]. Interestingly, recent evidence suggests that a particular
N-terminal-truncated MMP-2 isoform is induced by oxidative
stress [16] and promotes cardiomyocyte hypertrophy in the
absence of superimposed injury [17]. This is important because
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increased ROS levels apparently are major activators of MMP-2 in
hypertension [11,18–20], and antioxidant drugs reduced MMP
activity and protected against hypertensive cardiac hypertrophy,
particularly in experimental models with enhanced angiotensin II
activity [11,19].
β-Adrenergic blockers are widely used in hypertensive patients.
However, the mechanisms by which β-blockers may attenuate or
prevent hypertensive cardiac hypertrophy have not been clearly
deﬁned. In this regard, nebivolol is a cardioselective β1-adrenergic
receptor antagonist that, in addition to its effects on β-adrenergic
receptors, exerts antioxidants effects [20–23]. This particular
property of nebivolol may explain why this β-blocker has been
considered superior to other β-blockers such as metoprolol after
myocardial infarction [21] or to prevent the vascular proﬁbrotic
alterations and remodeling associated with hypertension [20].
However, it is not clear whether antioxidant effects and the
apparent superiority of nebivolol compared to metoprolol are
consistently found. In this study, we hypothesized that treatment
with either nebivolol or metoprolol could attenuate hypertension-
induced cardiac oxidative stress, MMP-2 activation, and LVH at
therapeutic doses that reduce blood pressure. Whereas antioxi-
dants effects have been ascribed to metoprolol in some recent
studies [24–26], it is not clear whether metoprolol and nebivolol
have antioxidant effects at therapeutic doses. This is a very
important issue because many drugs with putative antioxidant
effects require high concentration or show antioxidant effects only
under in vitro conditions.
Materials and methods
Animals and treatments
The study complied with the guidelines of the Faculty of
Medicine of Ribeirao Preto, University of Sao Paulo, and the
animals were handled according to the guiding principles pub-
lished by the National Institutes of Health. Male Wistar rats (180–
200 g) obtained from the colony at the University of São Paulo
were maintained on a 12-h light/dark cycle at 25 1C with free
access to rat chow and water. Two-kidney one-clip (2K1C) hyper-
tension was induced as previously described [10]. A silver clip
(0.2 mm) was placed in the left renal artery of rats under
anesthesia with ketamine (100 mg/kg) and xylazine (10 mg/kg)
ip. Sham-operated rats underwent the same surgical procedure
except for the clip placement. Tail systolic blood pressure (SBP)
was assessed weekly by tail-cuff plethysmography.
Treatments were started 6 weeks after surgery and maintained
for 4 weeks. The animals were randomly assigned to one of
six groups: 2K1C or sham animals that received vehicle (ethanol
2% v/v), 2K1C and sham animals that received metoprolol
(Meto) at 20 mg kg1 day1 (Selozok; AstraZeneca), and 2K1C and
sham animals that received nebivolol (Nebi) at 10 mg kg1 day1
(Nebilet Biolab). The drugs were given by gavage, and the doses
were chosen on the basis of previous studies using the same doses
of both β-blockers, which produced similar antihypertensive
effects [20,21,27].
Harvesting of the hearts and histological analysis
The animals were weighed and anesthetized, and the thoracic
cavity was opened to expose the still-beating heart. The hearts
were rapidly removed, rinsed in ice-cold 0.9% saline solution,
blotted, weighed, and ﬁxed as a whole in phosphate-buffered 10%
formalin (pH 7.3) for histological study. Both ventricles from each
heart were isolated and cut into two fragments by a midventri-
cular coronal section. Each block was serially cut in the same
direction and 4-μm-thick sections were stained with hematoxylin
and eosin. The left ventricular wall and septum thickness and the
area corresponding to the left ventricular chamber were deter-
mined in the ﬁrst three histological sections of each block.
Morphometrics analyses were carried out with ImageJ software
developed at the U.S. National Institutes of Health and available on
the Internet at http://rsb.info.nih.gov/nih-image. Average myocyte
diameter was determined from 20 measurements in each ven-
tricle, which were made at a magniﬁcation of 400 in long-
itudinally oriented myoﬁbers. Myocyte diameter was obtained in
the region of the nucleus of those cells in which the nuclear
envelope was sharply deﬁned at both ends, which corresponds to
the nucleus length and to its position at an equal distance from the
sides of the myocytes. The measurements were done with the
Leica Qwin software (Leica Imaging Systems Ltd, Cambridge, UK)
in conjunction with a Leica microscope (Leica DMR, Leica Micro-
systems Wetzlar GmbH, Wetzlar, Germany), videocamera, and
online computer. To estimate the collagen area (%) of ﬁbrosis in
picrosirius red-stained sections, quantitative examination of the
left ventricular and septum myocardium was carried out on a
medium-power light-microscopic ﬁeld (400). For each heart, 15
ﬁelds per region per rat were randomly selected and analyzed
using Leica Qwin software (Leica Imaging Systems). The mean
value was subsequently calculated.
Assessment of cardiac ROS and nitrotyrosine levels
Dihydroethidium (DHE; Sigma) was used to evaluate in situ
production of ROS [28,29]. Brieﬂy, the heart tissue was embedded
in Tissue-Tek. Left ventricle sections (5-μm-thick slices) were
incubated in 10 mmol/L DHE (diluted in 0.01% dimethyl sulfoxide;
Sigma) for 30 min and then washed three times with cold
phosphate-buffered saline (PBS; Sigma), pH 7.4, as previously
described [10]. Sections were examined by confocal microscopy
(Leica Model SPE, Leica Imaging Systems Ltd) using λex 405 nm
laser excitation [28]. The image was captured at 400 and red
ﬂuorescence was measured using the ImageJ Program (National
Institutes of Health). Some experiments were performed after
preincubation for 1 h with diphenyliodonium (DPI; 100 μmol/L; an
inhibitor of ﬂavoproteins), tiron (1 mmol/L; a superoxide scaven-
ger), or superoxide dismutase conjugated with polyethylene glycol
(PEG–SOD; 200 U/ml).
Lucigenin-derived chemiluminescence assay was also utilized
to evaluate superoxide anion production, as previously described,
with little modiﬁcation [30]. Brieﬂy, left ventricle homogenates
were prepared in phosphate buffer, pH 7.4 (KH2PO4 50 mM, EDTA
1 mM, sucrose 150 mM) and immediately transferred (50 μl) to the
luminescence microplate, and 175 μl of phosphate buffer with
5 μmol/L lucigenin was added. After background measurement,
300 mM NADPH was added to reaction (ﬁnal volume of 250 μl).
Luminescence was measured at 37 1C every second for 15 min in a
luminometer (Orion II Luminometer, Berthold). Background sig-
nals from samples were subtracted from the NADPH-driven signals
and the results were normalized by left ventricle dry weight and
reported as relative luminescence units (RLU)/mg.
To assess nitrotyrosine formation in the heart, 5-mm-thick
frozen sections were ﬁxed in acetone and incubated with 3%
H2O2 in water for 10 min at room temperature to block tissue
peroxidase activity. Then the tissue sections were incubated for 1 h
with a speciﬁc rabbit anti-nitrotyrosine antibody (Millipore, USA)
in dark humidiﬁed chambers. The samples were washed three
times, and an anti-rabbit horseradish peroxidase (HRP)-conju-
gated secondary antibody was added to the sections for 1 h at
room temperature and then washed three times with cold PBS.
Positive staining appeared as a dark brown color visualized by
adding 3,30-diaminobenzidine tetrahydrochloride chromogen
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buffer for 20 min followed by three washes with cold PBS (all
solutions were from an anti-rabbit poly-horseradish peroxidase
immunohistochemistry detection kit, Chemicon, USA, DAB-150).
Sections were counterstained with hematoxylin and examined by
optic microscopy (Leica Imaging Systems Ltd) and the image was
captured at 400. The amounts of nitrotyrosine in stained
sections were obtained by quantiﬁcation of the immunoreactivity
shown as brown color intensity and examined by two skilled
blinded observers. The evaluation of immunoreactivity was scored
qualitatively and quantitatively from 1 (low) to 5 (strong). Each
score reﬂects changes in the intensity of staining.
Measurement of cardiac MMP-2 levels by gelatin zymography
Gelatin zymography of MMP-2 was used to measure MMP-2
levels in left ventricle (LV) samples as previously described [11,12].
Brieﬂy, frozen LV samples (ﬁve per group) were homogenized in
ice-cold RIPA buffer (500 ml for each 0.1 g of LV sample) containing
1 mM 1,10-ortho-phenanthroline, 1 mM phenylmethanesulfonyl
ﬂuoride, and 1 mM N-ethylmaleimide. The samples were placed
on ice within a refrigerator for 30 min with gentle stirring and
then centrifuged at 10,000 g for 15 min. The protein concentra-
tions were measured using the Bradford method (Sigma). There-
after, 60 mg of protein was diluted 1:1 with sample buffer (ﬁnal
concentration: 2% SDS, 125 mM Tris–HCl, pH 6.8, 10% glycerol, and
0.001% bromophenol blue) and subjected to electrophoresis on
12% SDS–polyacrylamide gel electrophoresis copolymerized with
gelatin (0.05%) as the substrate. After electrophoresis was com-
pleted, the gel was incubated for 1 h at room temperature in a 2%
Triton X-100 solution, washed, and incubated at 37 1C overnight in
Tris–HCl buffer, pH 7.4, containing 10 mmol/L CaCl2. The gels were
stained with 0.05% Coomassie Brilliant Blue G-250 and then
destained with 30% methanol and 10% acetic acid. Gelatinolytic
activity was detected as an unstained band against the background
of Coomassie blue-stained gelatin. Enzyme activity was assayed by
densitometry using ImageJ software. The MMP-2 forms were
identiﬁed as bands at 75, 72, and 64 kDa.
Fig. 1. Systolic blood pressure (mm Hg) measured by the tail-cuff method before
and after treatment with vehicle (control), metoprolol, or nebivolol. Data are
shown as the mean 7 SEM (n ¼ 11–14/group). nnP o 0.05 vs the 2K1C þ Nebi or
the 2K1C þ Meto group. #P o 0.05 vs the respective sham group.
Fig. 2. Effects of treatment with β-blockers on hypertension-induced cardiac remodeling. (A) Representative photomicrographs of transverse heart sections used to
determine left ventricle area. (B) Heart weight/body ratio. (C) Left ventricle wall thickness. (D) Septum wall thickness. Data are shown as the mean 7 SEM (n ¼ 5 or 6/
group). nP o 0.05 vs the sham group. #P o 0.05 vs the 2K1C group.
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in situ zymography and immunoﬂuorescence to assess gelatinolytic
activity and MMP-2 expression
in situ MMP activity was measured in frozen LV using DQ gelatin
(E12055, Molecular Probes, Eugene, OR, USA) as a ﬂuorogenic
substrate [31]. Brieﬂy, LV samples were embedded in Tissue-Tek
and cut into 5-μm sections with a cryostat. Sample sections were
incubated with 1.0 mg/ml DQ gelatin in Tris–CaCl2 buffer (50 mM
Tris, 10 mM CaCl2, 1 mM ZnCl2) in dark humidiﬁed chambers for
1 h. The sections were examined with ﬂuorescence microscopy
(Leica Imaging Systems Ltd) and the image was captured at a
magniﬁcation of 400 . Proteolytic activity was detected as bright
green ﬂuorescence, which indicates substrate breakdown, and was
evaluated using the ImageJ Program (National Institutes of Health).
To evaluate MMP-2 expression, 5-μm tissue sections were
incubated with mouse anti-MMP-2 monoclonal antibody
(MAB3308, Chemicon International, Temecula, CA, USA) for 1 h
in a dark humidiﬁed chamber (at a 1:1000 dilution) [11]. Green
ﬂuorescence was visualized by adding a ﬂuorescein-conjugated
anti-mouse secondary antibody (1:200; FI 2000, Vector Labora-
tories, USA) for 1 h. To conﬁrm the speciﬁcity of antibodies, the
primary antibody was omitted and substituted by PBS 1% bovine
serum albumin (BSA). Fluorescein did not bind nonspeciﬁcally to
the tissue sections. MMP-2 expression was detected as bright
green ﬂuorescence and was evaluated using the ImageJ software.
Western blot analysis of protein kinase B/Akt (AKT)
AKT phosphorylation state was assessed in the rat hearts
because increases in the basal phosphorylation state of AKT
promote cardiac hypertrophy [32]. Moreover, AKT has been shown
to mediate hypertrophic effects associated with stimulation of β-
adrenergic receptors [33]. Therefore, examining the effects of β-
adrenergic blockers on AKT phosphorylation state could offer
additional mechanistic insight to this study.
Brieﬂy, heart extracts were homogenized in cold RIPA buffer.
Forty micrograms of protein extracts was separated by SDS–PAGE
using a12% polyacrylamide gel. The proteins were transferred onto
nitrocellulose membranes (GE Healthcare, Madison, WI, USA). After
being blocked in 5% BSA, membranes were incubated overnight at
4 1C with primary antibody directed against phospho-AKT (Ser473)
or total AKT (1:1000; Cell Signaling). Then the membranes were
incubated with HRP-labeled secondary goat anti-rabbit antibody
(1:1000; Millipore) and revealed with an ECL chemiluminescence
kit (GE Healthcare).
Fig. 3. Effects of treatment with β-blockers on myocyte diameter and collagen area. (A) Representative photomicrographs of sections from left ventricle myocytes (original
magniﬁcation 400 ). (B) Representative photomicrographs of sections from left ventricle stained with picrosirius red (original magniﬁcation 400 ). (C) Values of minor
diameter of myocytes. (D) Values of collagen surface area (%) in the left ventricle and septum. Data are shown as the mean 7 SEM (n ¼ 5–7/group). nP o 0.05 vs the sham
group. #P o 0.05 vs the 2K1C group.
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Statistical analysis
The results are expressed as means 7 SEM. Between-group
comparisons were carried out with two- or one-way analysis of
variance followed by the Tukey test. A probability value o0.05
was considered signiﬁcant.
Results
The two β-blockers exerted similar antihypertensive effects
SBP increased from baseline (120 mm Hg) to approximately
200 mm Hg in 2K1C hypertensive rats, whereas no signiﬁcant
Sham
Sham+Nebi
50 µm 
2K1C
2K1C+Nebi
2K1C+MetoSham+Meto
Sham 2K1C
Sham+Nebi 2K1C+Nebi
2K1C+Meto
50 µm 
Sham+Meto
Fig. 4. (A) Representative confocal photomicrographs (original magniﬁcation 400 ) of cardiac sections incubated with DHE. Red ﬂuorescence represents reactive oxygen
species production. (B) Representative photomicrographs of nitrotyrosine immunostaining performed in left-ventricular cryosections (original magniﬁcation 400 ).
(C) Quantiﬁcation of left-ventricular lucigenin chemiluminescence. (D) Quantiﬁcation of left-ventricular ﬂuorescence of DHE by confocal microscopy using λex 405 nm laser
excitation. (E) Results for positive controls. This graph shows increased DHE oxidation in 2K1C hypertension, which decreased with preincubation for 1 h with 200 U/ml
PEG–SOD, or 100 μmol/L DPI, or 1 mmol/L tiron. (F) Quantiﬁcation of left-ventricular nitrotyrosine expression. Data are shown as the mean 7 SEM (n ¼ 5–7/group).
nP o 0.05 vs the sham group. #P o 0.05 vs the 2K1C group.
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changes were found in the sham-operated group (P o 0.05;
Fig. 1). Treatment with drugs was started after 6 weeks of
hypertension, and similar decreases in SBP were found in 2K1C
animals treated with nebivolol or with metoprolol (from approxi-
mately 200 to 162719 and 167717 mm Hg, respectively; P o
0.05; Fig. 1). No signiﬁcant changes were found in sham-operated
animals.
Both β-blockers attenuated hypertension-induced cardiac remodeling
Representative photomicrographs of transverse heart sections
are shown in Fig. 2A. Hypertension increased all parameters
reﬂecting cardiac hypertrophy, including heart weight/body
weight ratio, LV wall thickness, and septum wall thickness, and
treatment with either metroprolol or nebivolol attenuated
hypertension-induced alterations in these (all P o 0.05; Fig. 2B–
D, respectively), except for heart weight/body weight ratio in
animals treated with metoprolol, which only tended to decrease
with this treatment (P 4 0.05; Fig. 2B). No signiﬁcant changes
were found in sham-operated animals treated with drugs.
Both β-blockers attenuated myocyte hypertrophy and proﬁbrotic
alterations associated with hypertension
The minor diameter of myocytes and ﬁbrosis in LV sections
were evaluated to assess further alterations associated with
hypertension, and representative photomicrographs are shown
in Fig. 3A and B, respectively. As expected, hypertension induced
signiﬁcant myocyte hypertrophy and ﬁbrosis in the 2K1C group
compared to the sham group, and treatment with both metoprolol
and nebivolol reduced myocyte hypertrophy and collagen deposi-
tion in 2K1C rats (P o 0.05 vs untreated 2K1C group; Fig. 3C and
D). No signiﬁcant changes were observed in the sham-operated
groups.
Both β-blockers attenuated cardiac oxidative and nitrosative stress
associated with hypertension
Fig. 4A and B show representative confocal photomicrographs
of ROS detection by DHE and nitrotyrosine expression in LV from
rats, respectively. To further validate oxidative stress assessed by
DHE, ROS formation was also studied using a lucigenin assay
(Fig. 4C). Hypertension consistently increased cardiac ROS levels
Fig. 5. (A) Representative SDS–PAGE gelatin zymogram of left ventricle samples. Values for (B) 75-kDa MMP-2, (C) 72-kDa MMP-2, and (D) 64-kDa MMP-2 isoforms and
(E) total MMP-2 (75 þ 72 þ 64 kDa MMP-2) are shown. Data are shown as the mean 7 SEM (n ¼ 11 or 12/group). nP o 0.05 vs the sham group. #P o 0.05 vs the
2K1C group.
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detected by DHE (Fig. 4A and D), nitrotyrosine expression (Fig. 4B
and E), and lucigenin-derived chemiluminescence (Fig. 4C) com-
pared to the sham-operated group (all P o 0.05). Interestingly,
treatment with both β-blockers signiﬁcantly attenuated all those
alterations associated with hypertension (all P o 0.05; Fig. 4A–D,
and F). Fig. 4E shows the results for positive controls. The increases
in DHE oxidation found in 2K1C hypertension were attenuated
after preincubation for 1 h with PEG–SOD, DPI, or tiron (all P o
0.05; Fig. 4E).
Whereas nebivolol attenuated hypertension-induced increases in
cardiac MMP-2 levels, metoprolol only tended to exert such an effect
A representative zymogram of cardiac extracts is shown in
Fig. 5A, which shows three bands corresponding to three isoforms
of MMP-2: 75, 72, and 64 kDa. Hypertension increased the cardiac
levels of both the 75- and the 72-kDa MMP-2 isoform, but not the
64-kDa isoform, compared to the sham-operated group (Fig. 5B–D,
respectively), thus resulting in increased total MMP-2 (P o 0.05;
Fig. 5E). Treatment with nebivolol attenuated hypertension-
induced increases in different MMP-2 isoforms, thus lowering
total MMP-2 levels (P o 0.05; Fig. 5B, C, and E). In contrast to the
effects of nebivolol, treatment with metoprolol tended to decrease
cardiac MMP-2 levels, but no signiﬁcant effects were found (all P
4 0.05; Fig. 5B–E).
Both β-blockers attenuated hypertension-induced increases in cardiac
in situ gelatinolytic activity and MMP-2 expression
To further improve our assessment of cardiac MMP activity and
MMP-2 expression, we measured in situ gelatinolytic activity and
assessed MMP-2 expression by immunoﬂuorescence. Representa-
tive photomicrographs showing both assessments in cardiac
samples are shown in Fig. 6A and B. Increased gelatinolytic activity
and MMP-2 levels were found in hearts from 2K1C hypertensive
rats compared to sham-operated controls (P o 0.05; Fig. 6C and D,
Fig. 6. in situ gelatinolytic activity and MMP-2 expression in the left ventricles from rats. (A) Representative photomicrographs of gelatinolytic activity and (B) MMP-2
staining in the left ventricles (original magniﬁcation 400 ). (C) Quantiﬁcation of left ventricle surface area covered by bright green ﬂuorescence, which reﬂects gelatinolytic
activity. (D) Green ﬂuorescence intensity, which reﬂects MMP-2 expression in cardiac tissue. Values are shown as means 7 SEM (n ¼ 4–6/group). nP o 0.05 vs the sham
group. #P o 0.05 vs the 2K1C group.
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respectively). Treatment with nebivolol or metoprolol almost
completely blunted hypertension-induced increases in both
in situ gelatinolytic activity and MMP-2 expression in the hearts
from hypertensive animals (P o 0.05; Fig. 6C and D, respectively).
Neither β-blocker affected AKT phosphorylation state
Increased AKT phosphorylation is a critical mechanism leading
to cardiomyocyte and cardiac hypertrophy [32], which could be
reversed by therapy with β-blockers [33]. Although we found
signiﬁcant increases in the levels of phospho-AKT in hypertensive
rats (P o 0.05; Fig. 7A and B), treatment with β-blockers did not
affect this alteration.
Discussion
This is the ﬁrst study to report that both nebivolol and
metoprolol used at doses that resulted in similar antihypertensive
effects can equally reverse hypertensive cardiomyocyte and LV
hypertrophy in association with antioxidant effects and lower LV
MMP activity.
Previous studies have compared the effects of nebivolol and
metoprolol under different conditions [20–22], and most studies
showed that nebivolol is superior to metoprolol in protecting
against the activation of pathophysiological mechanisms promot-
ing cardiovascular dysfunction. For example, nebivolol, but not
metoprolol, blunted cardiac NADPH oxidase activation after myo-
cardial infarction, improved LV dysfunction, and inhibited cardio-
myocyte hypertrophy found during this condition [21]. In line with
those ﬁndings, nebivolol, but not metoprolol, attenuated the
vascular remodeling associated with increased oxidative stress
and MMP activation in hypertensive rats [20]. Therefore, at least
some studies support the idea that nebivolol induces effects
beyond those usually found with conventional β1-blockers
[20,21]. However, our present results suggest that this idea is
probably not valid in the particular setting of experimental
hypertensive LV hypertrophy. Indeed, we studied different β-
blockers that apparently have different pharmacological proper-
ties but exert similar protective effects. This important observation
suggests that blocking β-adrenergic receptors is the main reason
explaining how β-blockers reverse hypertensive LV hypertrophy.
Transgenic mice overexpressing β1-adrenergic receptors
showed increased MMP-2 levels and enhanced cardiac remodeling
[34]. Whereas activation of β-adrenergic receptors upregulates
MMPs, both in vivo and in vitro [34–37], little is known about the
effects of β-blockers on MMP levels and activity, and our results
consistently show that treatment with β-blockers signiﬁcantly
blunts hypertension-induced increases in MMP-2 expression and
activity, although the effects of metoprolol on MMP-2 levels
assessed by zymography were slightly less important than those
found with nebivolol. However, we used three different methods
to assess MMP activity in the heart, and similar results were found
with independent approaches, clearly showing that treatment
with both β-blockers blunts 2K1C hypertension-induced increases
in cardiac MMP-2 levels and activity.
Mechanistically, our ﬁndings suggest that both β-blockers tested
here may have blunted β-adrenergic receptor-stimulated ROS
formation and MMP-2 activation, and this effect may have had
critical consequences in the present hypertension model. This
suggestion is supported by previous studies showing that activa-
tion of β-adrenergic receptors increases ROS formation as a result
of increased protein kinase C activity leading to subsequent NADPH
oxidase activation [38–40]. Increased ROS levels, in turn, activate
MMPs and promote cardiac hypertrophy [11,17,19]. In agreement
with suggestion, we found increased ROS formation, lucigenin-
derived chemiluminescence, and nitrotyrosine expression asso-
ciated with augmented MMP-2 levels and activity in the hearts
from 2K1C hypertensive animals, and all those alterations were
signiﬁcantly attenuated after treatment with both β1-blockers, thus
suggesting that blocking β-adrenergic receptors is critical to reverse
hypertension-induced LV hypertrophy. Interestingly, although
increased AKT phosphorylation has been shown to be an important
mechanism underlying hypertrophic modiﬁcations [32], potentially
Fig. 7. Western blot analysis of protein kinase B/Akt (AKT) phosphorylation state. (A) Representative Western blot of phospho-AKT (Ser473) and total AKT. (B) Phospho-AKT-
to-total AKT ratio, which reﬂects the state of AKT phosphorylation. Values are shown as means 7 SEM (n ¼ 6/group). nP o 0.05 vs the sham groups.
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dependent on the stimulation of β-adrenergic receptors [33], our
results suggest that this mechanism is not relevant to explain the
pharmacological effects shown here.
Although various MMPs are expressed in the myocardium,
growing evidence indicates that MMP-2 plays a major role in
cardiac remodeling [12,13,17]. Indeed, this particular MMP is
found at the ECM and within cardiomyocytes, and unbalanced
MMP-2 activity impairs ECM integrity and cardiomyocyte function
[41,42]. Although increased MMP-2 activity promotes collagen
degradation, there is also increased expression and activity of
proﬁbrotic factors resulting in collagen accumulation [11,43].
Consistent with previous studies, we found augmented collagen
accumulation in the LV from hypertensive rats [5,10,44], and
treatment with nebivolol or metoprolol was equally effective in
decreasing hypertensive collagen deposition.
The methods used to assess ROS production in this study
deserve some comment. There are some controversial issues with
both DHE and lucigenin assays, particularly with respect to self-
propagation reactions with the use of ﬂuorescent probes such as
DHE [28,29] and the possibility of redox cycling of lucigenin [45,46],
which may limit their utility to assess superoxide formation, as
previously discussed [28,29,45,46]. Although the main goal of this
study was not to detect a speciﬁc oxidant, it is important to note
that the results obtained with both assays were in full agreement
with nitrotyrosine results. Importantly, we used confocal micro-
scopy using excitation at 405 nm for the DHE assay, which mini-
mizes possible artifacts [28]. Moreover, we used lucigenin at a
5 μmol/L concentration, which has been suggested as a non-redox-
cycling concentration [47]. Therefore, our results may provide
relevant information about overall oxidant production.
In conclusion, we found evidence that two β1-blockers with
different properties attenuate hypertension-induced LV hypertro-
phy and cardiac collagen deposition in association with signiﬁcant
cardiac antioxidant effects and MMP-2 downregulation. Because
both β1-blockers exerted similar antihypertensive effects, our results
suggest a critical role for β1-adrenergic receptors in mediating those
effects. Clinical studies should be carried out to compare the effects
of various β1-blockers on hypertension-induced LV hypertrophy.
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